Geron swings to Q3 2026 net profit of $1.35 million from year-earlier loss
GERN•Geron reported third-quarter 2026 net income of $1.35 million, compared with a year-earlier net loss of $18.43 million. Product revenue rose 27% to $60.11 million, and the company lowered operating expense guidance to $220 million–$230 million.
1. Quarterly results
Geron swung to third-quarter 2026 net income of $1.35 million from a year-earlier net loss of $18.43 million. Product revenue, net rose 27% year over year to $60.11 million, while total costs and operating expenses fell 11% to $54.39 million.
2. Trial and guidance
Geron discontinued the Phase 3 IMpactMF trial after an independent committee assessed that it was unlikely to meet its overall-survival endpoint. The company began a targeted European RYTELO launch, with availability expected in Germany by year-end and France in 2027. FY26 product revenue guidance remained at the mid-to-high end of $220 million–$240 million, while operating expense guidance fell to $220 million–$230 million.
